Filter Results

Clinical Studies


  • A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a) (OCEAN(a)) Rochester, Minn.

    The purpose of this study is to assess the impact of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein (a) (Lp[a]) ≥ 200 nmol/L. The primary objective is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death, myocardial infarction, or urgent coronary revascularization in these patients.

  • Cardiovascular Phenotype Driven Genomic Research Exploration Study Rochester, Minn.

    The purpose of this study is create a biorepository of patients/families where there is a clustering of a cardiovascular disease (CVD) phenotype with suspected genetic etiology, in order to conduct gene discovery.

  • Cascade Screening for Awareness and Detection of Familial Hypercholesterolemia (CASCADE-FH) Rochester, Minn.

    The CASCADE Familial Hypercholesterolemia Registry will track therapy, clinical outcomes, and patient-reported outcomes over time aiming to increase familial hypercholesterolemia awareness, promote optimal disease management, and improve outcomes. This study is not recruiting family members of FH patients at this time.

  • Familial Hypercholesterolemia Identification REgistry (FHIRE) (FHIRE) Rochester, Minn.

    The purpose of this study is to develop a registry of molecularly confirmed Familial Hypercholesterolemia (FH) cases in conjunction with the retrospective FHIRE study (IRB# 18-009654) in order to identify and offer genetic testing to Mayo Clinic patients with suspected FH.

  • The electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment (eMERGE IV) Rochester, Minn.

    The electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment Study is a multisite study funded by the National Human Genome Research Institute (NHGRI) to investigate the clinical utility of polygenic risk scores for common conditions in adults and children. eMERGE researchers aim to learn about how people’s family history and genetic makeup affect their risk of developing common conditions such as heart disease, diabetes, and cancer, and about how to use this information to help them reduce their risk. The study will recruit 25,000 participants from around the country, including groups who are underrepresented in biomedical research.

    Each participant will provide a biospecimen for genetic testing and fill out surveys about personal and family health history. Participants will receive a Genome Informed Risk Assessment (GIRA) report that includes their estimated risk for common conditions based on genetic testing results, clinical variables, and family history. The GIRA report will be uploaded to the participant's electronic health record and is meant to help participants and providers interpret risk for common conditions. A subset of participants will receive their results from a member of the study team in-person or by a virtual appointment.

Closed for Enrollment